1. CX-072 (pacmilimab), a Probody PD-L1 inhibitor, in combination with ipilimumab in patients with advanced solid tumors (PROCLAIM-CX-072): a first-in-human, dose-finding study. Issue 7 (23rd July 2021) Authors: Sanborn, Rachel E; Hamid, Omid; de Vries, Elisabeth GE; Ott, Patrick A; Garcia-Corbacho, Javier; Boni, Valentina; Bendell, Johanna; Autio, Karen A; Cho, Daniel C; Plummer, Ruth; Stroh, Mark; Lu, Lawrence; Thistlethwaite, Fiona Journal: Journal for immunotherapy of cancer Issue: Volume 9:Issue 7(2021) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗